Skip to content

An Evaluation Of Orphan Drug Company NPS Pharmaceuticals:’s Perspective

January 3, 2013

Orphan Drug company NPS Pharmaceuticals is evaluated in a recent article titled, “A Comprehensive Analysis of NPS Pharmaceuticals”. The New Jersey pharmaceutical company had its orphan drug Gattex (Teduglutide) approved for the treatment of Short Bowel Syndrome (SBS) in December 2012. The company also has another orphan drug, Natpara, for the treatment of Hypoparathyroidism.

The article evaluates NPS Pharmaceuticals for the following :

  1. Market strategy
  2. Industry Trends
  3. R&D productivity and product pipeline
  4. Alliances with other firms
  5. International presence
  6. Regulatory environment and news
  7. Fundamentals and Sales trends.

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: